Table of Contents
Volume 2015, Article ID 126975, 5 pages
Research Article

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis

1Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
2Department of Medicine, Duke University, Durham, NC 27710, USA

Received 16 July 2015; Revised 15 September 2015; Accepted 28 September 2015

Academic Editor: Domenico Prisco

Copyright © 2015 Sarah Yentz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Y. Lee, M. N. Levine, R. I. Baker et al., “Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer,” The New England Journal of Medicine, vol. 349, no. 2, pp. 146–153, 2003. View at Publisher · View at Google Scholar
  2. T. Delate, D. M. Witt, D. Ritzwoller et al., “Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer,” Oncologist, vol. 17, no. 3, pp. 419–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Laposata, Coagulation Disorders: Diagnostic Standards of Care, Demos Medical Publishing, New York, NY, USA, 2010.
  4. L. Bara, E. Billaud, G. Gramond, A. Kher, and M. Samama, “Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration,” Thrombosis Research, vol. 39, no. 5, pp. 631–636, 1985. View at Publisher · View at Google Scholar · View at Scopus
  5. H. K. Nieuwenhuis, J. Albada, J. D. Banga, and J. J. Sixma, “Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin,” Blood, vol. 78, no. 9, pp. 2337–2343, 1991. View at Google Scholar · View at Scopus
  6. M. Alhenc-Gelas, C. Jestin-le Guernic, J. F. Vitoux et al., “Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis,” Thrombosis and Haemostasis, vol. 71, no. 6, pp. 698–702, 1994. View at Google Scholar · View at Scopus
  7. E. A. Nutescu, S. A. Spinler, A. Wittkowsky, and W. E. Dager, “Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings,” Annals of Pharmacotherapy, vol. 43, no. 6, pp. 1064–1083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. J.-A. Wilson, K. Wilbur, E. Burton, and D. R. Anderson, “Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism,” Haemostasis, vol. 31, no. 1, pp. 42–48, 2001. View at Google Scholar · View at Scopus
  9. A. Bazinet, K. Almanric, C. Brunet et al., “Dosage of enoxaparin among obese and renal impairment patients,” Thrombosis Research, vol. 116, no. 1, pp. 41–50, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. W. Hainer, J. S. Barrett, C. A. Assaid et al., “Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study,” Thrombosis and Haemostasis, vol. 87, no. 5, pp. 817–823, 2002. View at Google Scholar · View at Scopus
  11. W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther, “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency,” Annals of Internal Medicine, vol. 144, no. 9, pp. 673–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Laposata, D. Green, E. M. Van Cott, T. W. Barrowcliffe, S. H. Goodnight, and R. C. Sosolik, “College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban,” Archives of Pathology and Laboratory Medicine, vol. 122, no. 9, pp. 799–807, 1998. View at Google Scholar · View at Scopus